Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Meijer, Inc. et al v. Ranbaxy Inc. et al
Case Number:
1:15-cv-11828
Court:
Nature of Suit:
Racketeer/Corrupt Organization
Judge:
Firms
- Berman Tabacco
- Cohen Milstein
- Hagens Berman
- Hilliard & Shadowen
- Kirkland & Ellis
- Mintz Levin
- Radice Law Firm
- Wexler Boley
Companies
Sectors & Industries:
-
June 16, 2016
Ranbaxy Can't Duck Antitrust Suit Over Generic Applications
A Massachusetts federal magistrate judge recommended on Thursday that no claims be dismissed from retailer Meijer's putative class action against pharmaceutical company Ranbaxy over the allegedly unfair competitive advantage it got from securing regulatory approvals for generic drugs it was not equipped to safely produce.
-
May 12, 2015
Ranbaxy Accused Of Filing Deceptive Drug Applications
Michigan-based retailer Meijer Inc. on Tuesday launched a putative class action in Massachusetts federal court accusing Ranbaxy Inc. of recklessly stuffing generic drug approval queues with deceptive applications in an effort to block or delay competitors from coming to market.